ClinicalTrials.gg
Not yet recruitingNCT07938580Updated Nov 16, 2026

Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia

A Phase 2 interventional study of Gecacitinib and Luspatercept in Myelofibrosis, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing jaktinib in Primary Myelofibrosis — 4 open to participants now, 4 under way, none of them phase 3. jaktinib · Primary Myelofibrosis.

Planned enrollment
7th of 10
31 · median 37
Started
2026
with 2 others
Phase 2
4 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Peking Union Medical College Hospital

Among the 10 studies testing jaktinib in Primary Myelofibrosis, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 2, and was the 10th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

4 of the 10 studies testing jaktinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About jaktinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing jaktinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
  3. Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
  4. No previous treatment with a Janus kinase inhibitor.
  5. Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, , , and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
  6. Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
  7. below 100 g/L, with or without red blood cell transfusion dependence.
  8. count of at least 75 × 10\^9/L.
  9. of at least 1.0 × 10\^9/L.
  10. Peripheral blood blasts of 10% or less.
  11. performance status of 0-2 and a of more than 6 months.
  12. Ability to independently provide written .

Exclusion criteria

Exclusion Criteria:

  1. anemia associated with iron, vitamin B12, or folate deficiency; or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.
  2. Active infection.
  3. A history of within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.
  4. Significant hepatic or renal dysfunction, or dysfunction of another major organ.
  5. Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:

    • Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
    • Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
    • Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute , version 5.0.
  6. Previous splenectomy.
  7. Previous treatment with any transforming growth factor-beta ligand inhibitor.
  8. Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.
  9. Suspected to gecacitinib, luspatercept, or drugs of the same class.
  10. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Gecacitinib + Luspatercept

    gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks

    Drug: Gecacitinib · Drug: Luspatercept

Interventions

  • Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10\^9/L and may be resumed when the platelet count recovers to at least 50 × 10\^9/L.

  • Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Anemia Response

    Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower.

    Time frame: 24 week

Secondary outcomes

  1. Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion

    Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions.

    Time frame: 24 week

  2. Time to Anemia Response

    Time from the first dose of study treatment to the first documented anemia response.

    Time frame: week 24

  3. Duration of Anemia Response

    The longest continuous duration of anemia response among participants who achieve an anemia response.

    Time frame: week 24

  4. Change From Baseline in Red Blood Cell Transfusion Amount and Frequency

    Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment.

    Time frame: week 24

  5. Change From Baseline in Hemoglobin

    Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits.

    Time frame: weeks 4, 8, 12, 16, 20, and 24

  6. SVR35

    Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline.

    Time frame: week 12 and 24

  7. DoMSR

    Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline.

    Time frame: week 24

  8. MPN-SAF TSS

    Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).

    Time frame: weeks 4, 8, 12, 16, 20, and 24

  9. Reduction in Fatigue Score

    Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score.

    Time frame: week 24

  10. Adverse Events

    Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded.

    Time frame: From the first dose through 28 days after the last dose.

  11. PFS

    Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first.

    Time frame: 12 month

  12. OS

    Time from the first dose of study treatment to death from any cause.

    Time frame: 12 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 68 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 25 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938580
Responsible party
Bing Han (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Bing Han
Contact
hanbing_li@sina.com.cn
01065295027

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion